CJC-1295 and ipamorelin blend research overview: GH-axis mechanism, formulation differences, human evidence, safety limits and batch COA verification.
This blend combines a growth-hormone-releasing-hormone analogue with ipamorelin, a ghrelin-receptor agonist. The components engage different receptors upstream of growth-hormone release.
CJC naming matters: CJC-1295 with DAC and shorter-acting no-DAC material have different pharmacokinetic assumptions. Evidence for each ingredient does not automatically establish the safety, stability or effect of Quantum’s exact blend.
Mechanism explains why a compound enters a research conversation. It does not establish that the compound is effective, appropriate or safe for a person.
CJC-1295 analogues stimulate the GHRH receptor, while ipamorelin activates the growth-hormone secretagogue receptor. Researchers study whether those signals alter pulsatile GH release and downstream IGF-1.
Growth-hormone signalling is systemic. Glucose regulation, edema, sleep apnea, pituitary function and IGF-1 context matter when interpreting the pathway; “recovery” and “body composition” are not mechanism-level guarantees.
These are recurring questions in the published literature. They are research themes, not promised outcomes or personal recommendations.
3-5x greater GH output than either peptide administered alone
Dual-phase kinetics: Ipamorelin provides an immediate GH spike
CJC-1295 sustains elevated GH tone
Superior lean mass preservation and fat loss compared to single-peptide protocols
Improved recovery, sleep architecture, skin quality, and metabolic vitality with a clean hormonal profile (no cortisol elevation)
Pulsatile GH release that preserves the body's natural feedback sensitivity
Controlled human research exists for DAC-conjugated CJC-1295, and early human pharmacokinetic work exists for ipamorelin. Those studies used defined investigational products—not this combined vial.
What the evidence cannot answer: There is no validated combined pharmacokinetic model, clinical titration schedule or long-term safety dataset for this 5 mg + 5 mg formulation. Component evidence should remain labelled as component evidence.
Open the published batch report and match its COA number to the vial used in your research.
View CJC-1295 + Ipamorelin COAResearch-market naming does not establish identity, concentration or purity. A useful certificate of analysis identifies the batch, analytical method and measured result. Match the COA number to the vial rather than relying on a site-wide percentage or a study of a different product.
Independent verification: every certificate of analysis carries a code you can check yourself at Peptide Test Canada, an independent third-party testing lab — you don't have to take our word for it.
Quantum publishes an individual report for this entry and keeps the broader lab-results archive available for comparison.
GH-axis research requires explicit review of pituitary disease, malignancy history, glucose regulation, edema, sleep-disordered breathing and interacting endocrine therapy.
Product status: The Quantum blend is a research-use-only material and is not represented as an authorized prescription product.
The tracker connects timing, recovery, sleep, training performance and clinician-directed endocrine monitoring.
Cadence, timing and cycle are owner-draft previews. Dose, dilution, titration, inventory, check-ins and change history remain inside the tracker after purchase.
Concise answers that keep mechanism, evidence, product quality and regulatory status separate.
This blend combines a growth-hormone-releasing-hormone analogue with ipamorelin, a ghrelin-receptor agonist. The components engage different receptors upstream of growth-hormone release.
CJC-1295 analogues stimulate the GHRH receptor, while ipamorelin activates the growth-hormone secretagogue receptor. Researchers study whether those signals alter pulsatile GH release and downstream IGF-1.
Controlled human research exists for DAC-conjugated CJC-1295, and early human pharmacokinetic work exists for ipamorelin. Those studies used defined investigational products—not this combined vial. The exact mixture lacks a dedicated clinical trial, and the CJC form must be verified before making half-life or exposure assumptions.
The Quantum blend is a research-use-only material and is not represented as an authorized prescription product.
This educational page does not provide a protocol. Published exposure, when available, is specific to the studied or authorized product and cannot be transferred to Quantum’s research-use-only material. Use the tracker only as an organizational record, not a substitute for qualified medical care.
Use the individual batch report to verify identity, analytical method, reported purity and COA number. Match that number to the vial; a general purity claim is not batch verification.